関連する実験動画
Updated: Sep 10, 2025
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
15.9K
口腔の粘膜メラノーマにおける生存率と予後要因:メタ解析
Alberto Rodriguez-Archilla1,2, Pablo Valverde-Martinez1
1Department of Stomatology, Oral Medicine Unit, Faculty of Dentistry, University of Granada, Granada, Spain.
Journal of dental research, dental clinics, dental prospects
|August 22, 2025
まとめ
口腔メラノーマの生存率は低く,時間の経過とともに著しく低下しています. 潰瘍がなく,色素が濃い腫瘍は 予後が良く,潰瘍がなく,色素が薄い腫瘍は 最悪です.
科学分野:
- 腫瘍学
- 皮膚科
- 口腔医学
背景:
- 口腔メラノーマはしばしば口腔の血管化とリンパ流出により早期に転移する.
- 経口メラノーマ患者の予後が悪くなる
研究 の 目的:
- 異なる期間における口腔メラノーマの生存率を決定する.
- 口腔メラノーマの生存に影響を与える予後要因を特定する.
主な方法:
- PubMed,Web of Science,およびScopusで体系的な文献検索が行われました.
- 総合比率の汎用逆方差法とオッズ比率のマンテル・ヘンスゼル法を用いたメタ分析が行われました.
- 3767人の口腔メラノーマ患者を対象とした38件の研究が含まれた.
主要な成果:
- 全生存率は2年後の58%から5年後の29%に減少した.
- 皮膚の色素化が高い非潰瘍性口腔メラノーマは,5年生存率が最も高いことが示されました.
- 腫瘍の位置と性別は,口腔メラノーマの生存率に有意な影響を及ぼさなかった.
結論:
- 口腔メラノーマは低生存率と関連しています.
- 潰瘍や色素が悪い腫瘍は 口腔メラノーマの最悪な予後を示します
さらに関連する動画
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
376
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.6K
関連する概念動画
01:30Skin Cancer
4.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.5K
01:21Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453